WALD

Waldencast Plc (WALD) - Form 20-F Summary

Business Context and Reporting Period

This summary covers the Annual Report on Form 20-F for the fiscal year ended December 31, 2025. Waldencast Plc is a global multi-brand beauty and wellness platform organized as an "Up-C" structure, operating through two primary segments: Obagi Medical (professional skincare) and Milk Makeup (clean prestige makeup). The company is incorporated in Jersey and is a UK tax resident as of October 29, 2024. It is classified as an Emerging Growth Company and a Foreign Private Issuer.

Key Financial Metrics (Year Ended Dec 31, 2025)

Note: The 2025 Net Loss includes a non-cash goodwill impairment charge of $152.0 million and a loss on extinguishment of debt of $24.4 million.

Material Changes vs. Prior Period

• Revenue Decline: Net revenue decreased 0.7% to $272.1 million. While U.S. direct-to-consumer and retail channels grew, international Milk Makeup revenue fell $19.8 million due to soft consumption and lower retailer inventory levels.
• Goodwill Impairment: A significant non-cash impairment charge of $152.0 million was recorded ($132.1 million for Obagi Medical and $20.0 million for Milk Makeup) due to discrepancies between projected and actual performance post-acquisition.
• Debt Refinancing: The company refinanced its debt structure. It entered the Lumina Credit Agreement in November 2025 ($225.0 million facility) to repay the TCW Credit Agreement. This resulted in a $24.4 million loss on extinguishment of debt and increased interest expense (effective rate 19.1% vs. 8.7% in 2024).
• Strategic Transactions:
  • Acquisition: Acquired Novaestiq Corp. (July 2025) for U.S. rights to Saypha injectable fillers. Recognized a $6.2 million loss on acquisition.
  • Asset Sale: Sold Obagi Japan trademark rights to Rohto Pharmaceutical for $82.5 million, recognizing a $5.7 million gain.

Guidance, Outlook, and Risks

• Strategic Review: In August 2025, the Board initiated a review of strategic alternatives to maximize shareholder value. No specific transaction or timeline is guaranteed.
• Internal Controls: The company disclosed material weaknesses in internal control over financial reporting (ICFR) that were not fully remediated as of December 31, 2025. These relate to risk assessment, control activities, and monitoring. Full SOX 404(b) compliance is targeted for the fiscal year ending December 31, 2026.
• SEC Investigation: The company is subject to an ongoing SEC investigation regarding historical accounting practices and the restatement of financial results for predecessor periods. The company is cooperating but cannot predict the outcome or costs.
• Liquidity & Covenants: The Lumina Credit Agreement includes a financial covenant (Total Leverage Ratio) which was suspended until December 31, 2026, via a March 2026 amendment. Failure to comply could trigger an event of default.
• Regulatory Risks: Significant risks exist regarding FDA regulation of hydroquinone products (Obagi) and CBD ingredients (Milk), as well as the Modernization of Cosmetics Regulation Act (MoCRA).

Investor Verification Checklist

• Goodwill Valuation: Verify the assumptions used in the goodwill impairment test (discount rates, growth forecasts) given the narrow margin between carrying value and fair value for both reporting units.
• Debt Service Capacity: Assess the ability to service the Lumina Credit Agreement (14.75%+ interest rate, PIK interest) given the current operating loss and reliance on non-cash adjustments for Adjusted EBITDA.
• Internal Control Remediation: Monitor progress on remediation of material weaknesses in ICFR to ensure timely and accurate future reporting and avoid further regulatory penalties.
• Strategic Review Outcome: Track the status of the strategic review for potential M&A, divestitures, or recapitalization that could alter the capital structure.
• Regulatory Compliance: Monitor FDA actions regarding hydroquinone products and the commercial launch success of the Saypha injectable fillers.